MacroGenics, Inc.

NASDAQ:MGNX

Biotechnology

Healthcare
$1.98 +2.02%

+$0.08 today

Market cap
$126.54M
Beta
1.20
P/E (TTM)
-3.6
EPS (TTM)
-$1.11
52W Low $1.19High $4.64

Volume 0.93M

Average 0.98M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$81.04M

FY 2025 · Annual

Investing Cash Flow

-$114.10M

FY 2025 · Annual

Financing Cash Flow

$69.51M

FY 2025 · Annual

+7141.0% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(202.12M)(119.76M)(9.06M)(66.97M)(74.62M)
Depreciation & Amortization11.26M11.87M9.65M7.54M5.52M
Deferred Income Tax00000
Stock-Based Compensation23.13M20.44M18.37M29.44M14.29M
Change in Working Capital17.57M(6.13M)53.32M1.39M(28.33M)
Accounts Receivables12.7M(45.84M)45.86M6.06M(9.06M)
Inventory(6.42M)55K230K(2.19M)(7.91M)
Accounts Payables7.13M(10.86M)1.28M(1.53M)(280K)
Other Working Capital4.17M50.51M5.95M(948K)(11.08M)
Other Non-Cash Items6.33M6.63M(150.48M)(39.78M)2.1M
Operating Cash Flow(143.83M)(86.96M)(78.21M)(68.37M)(81.04M)
Capital Expenditures(6.2M)(3.62M)(1.76M)(3.71M)(1.91M)
Acquisitions (Net)0064K011K
Purchases of Investments(231.21M)(120.6M)(239.68M)(77.18M)(208.34M)
Sales of Investments200.8M194.94M161.3M190.03M96.14M
Other Investing Activities00040.16M0
Investing Cash Flow(36.61M)70.72M(80.08M)149.3M(114.1M)
Debt Repayment00(157K)00
Common Stock Issued117.82M1.09M1.17M3.44M129K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities4.96M574K149.35M960K69.39M
Financing Cash Flow122.78M1.66M150.36M960K69.51M
Effect of Forex Changes00000
Net Change in Cash(57.66M)(14.59M)(7.93M)81.88M(125.62M)
Free Cash Flow(150.03M)(90.58M)(79.97M)(72.08M)(82.95M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$74.6M
+ D&A$5.5M
+ Stock-Based Comp$14.3M
+ Deferred Tax$0
- Working Capital-$28.3M
+ Other Non-Cash$2.1M
= Operating Cash Flow-$81.0M
- Capex-$1.9M
= Free Cash Flow-$83.0M

Analysis

FY2025 free cash flow is -$83.0M. FCF conversion is 111.2% of net income. Operating cash flow was -$81.0M, with capex of -$1.9M. The largest bridge item is Working Capital at -$28.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 13, 2026
10-QQuarterly reportNov 12, 2026
8-KCurrent reportNov 12, 2026
3Initial statement of beneficial ownershipNov 3, 2026
4Statement of changes in beneficial ownershipNov 3, 2026

Does MGNX generate free cash flow?

MacroGenics, Inc. (MGNX) generated -$82.95M of free cash flow in fiscal 2025.

How much operating cash flow does MGNX produce?

Operating cash flow was -$81.04M, before capital expenditures of $1.91M.